文献速递胸部肿瘤

早期非小细胞肺癌免疫治疗应答的生物标志物

Biomarkers of response to immunotherapy in early stage non-small cell lung cancer.
PubMed 文献 · Eur J Cancer · 2023-02-17

综述探讨早期非小细胞肺癌(NSCLC)免疫检查点抑制剂(ICI)治疗的应答生物标志物。新辅助抗PD-(L)1单药的主要病理缓解率很少超过40%,PD-L1表达和肿瘤突变负荷与较高病理缓解率和生存相关。EGFR、STK11和KEAP1突变成为早期NSCLC治疗选择的关键检测。

要点

  • 新辅助抗PD-(L)1单药的主要病理缓解率很少超过40%,缺乏可靠生物标志物。
  • PD-L1表达与较高病理缓解率和生存相关,肿瘤突变负荷相关性较弱。
  • EGFR、STK11和KEAP1突变是早期NSCLC治疗选择的关键检测。

核心结论

  • 早期NSCLC免疫治疗仍需更成熟数据才能改变范式,但病理缓解率和无病生存报告令人鼓舞,尤其是新辅助多模式方案。

研究设计与样本

  • 综述,检索范围未在摘要中报告。

主要发现

  • 新辅助抗PD-(L)1单药的主要病理缓解率很少超过40%。
  • PD-L1表达与较高病理缓解率和生存相关,肿瘤突变负荷相关性较弱。
  • EGFR、STK11和KEAP1突变是早期NSCLC治疗选择的关键检测。
  • 新兴方法包括血液基比值、微生物群和基线瘤内TCR克隆性评估。
  • 循环肿瘤DNA在辅助ICI候选选择和新辅助治疗肿瘤反应监测中将有帮助。

关键数值与推荐

  • 抗PD-(L)1单药新辅助治疗的主要病理缓解率很少超过40%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 早期阶段改变范式前需要更成熟的数据。
  • 新辅助抗PD-(L)1单药的主要病理缓解率很少超过40%,缺乏可靠生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunotherapy with immune-checkpoint inhibitors (ICIs) targeting programmed cell death 1 or programmed death-ligand 1 has revolutionised the treatment of advanced non-small cell lung cancer (NSCLC) and has been investigated in early NSCLC, alone or in combination with chemotherapy, anti-CTLA-4 antibodies and radiotherapy. Although more mature data are needed before setting a change of paradigm in early stages, reports of pathological response rates and disease-free survival are promising, especially with neoadjuvant multimodality approaches. Nevertheless, major pathological response rates for neoadjuvant anti-PD-(L)1 monotherapy rarely exceed 40%, and biomarkers for characterising patients who may benefit the most from ICIs are lacking. These biomarkers have a distinct value from the metastatic setting, with highly different tumour biologies. Among the most investigated so far in this context, programmed death-ligand 1 expression and, to a lesser extent, tumour mutational burden seem to correlate better with higher pathological response rates and survival. Epidermal growth factor receptor, Serine/Threonine Kinase 11and Kelch-like ECH-associated protein 1 mutations rise as essential determinations for the treatment selection in early-stage NSCLC. Emerging and promising approaches comprise evaluation of blood-based ratios, microbiota, and baseline intratumoural TCR clonality. Circulating tumour DNA will be of great help in the near future when selecting best candidates for adjuvant ICIs, monitoring the tumour response to the neoadjuvant treatment in order to improve the rates of complete resections in the early stage.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Roulleaux Dugage M, Albarrán-Artahona V, Laguna JC, et al. Biomarkers of response to immunotherapy in early stage non-small cell lung cancer. Eur J Cancer. 2023. PMID: 36963241. doi:10.1016/j.ejca.2023.01.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。